Paul B. Watkins – 1 September 1995 – Immunosuppression therapy with cyclosporine is often hampered by significant interindividual variability in the metabolic clearance of the drug. It has been suggested that much of the variability in cyclosporine clearance is due to differences in the cytochrome P450 3A4 (CYP3A4) content in the liver and intestinal mucosa. A study was conducted in liver transplant recipients to characterize hepatic CYP3A4 variability during the first 10 days after surgery. The formation of 1′‐hydroxymidazolam (1′‐OH MDZ) was followed in the plasma after i.v.

Massimo Pinzani – 1 September 1995 – A consistent response to liver injury is the activation of resident mesenchymal cells known as lipocytes (Ito, fat‐storing cells) into a proliferating cell type. In cultured lipocytes, platelet‐derived growth factor (PDGF) is the most potent proliferative cytokine, but requires the activation‐dependent expression of its receptor protein (Friedman, S. L., and M. J. P. Arthur. 1989. J. Clin. Invest. 84:1780–1785); the role of PDGF receptor (PDGFR) in liver injury is unknown.

William C. Meyers – 1 September 1995

Peter P. Michielsen, Guy E. Boeckxstaens, Stanislas U. Sys, Arnold G. Herman, Paul A. Pelckmans, Wladimiro Jiménez – 1 September 1995

Robert H. Collins, Goran B. Klintmalm, Mark S. Cattral, Alan N. Langnas – 1 September 1995

John S. Radomski, Michael J. Moritz, Santiago J. Muñoz, Jacqueline R. Cater, Bruce E. Jarrell, Vincent T. Armenti – 1 September 1995 – Outcomes from 48 pregnancies in 34 female liver transplant recipients were analyzed. Data were collected via interviews, questionnaires, and hospital records. All recipients were treated with cyclosporine‐based immunosuppression except 2 patients treated with FK506 and 2 treated with no immunosuppression. The age at conception was 26.1 ± 5.9 years (mean ± SD) with a transplant interval (time from transplantation to conception) of 2.9 ± 2.5 years.

Teerha Piratvisuth, J. Michael Tredger, Karen A. Hayllar, Roger Williams – 1 September 1995 – The role of true cold ischemia times (CIT) and rewarming ischemia times (WIT) in determining outcome after liver transplantation was investigated in 230 adult recipients.

William T. Abraham, Marije E. Lauwaars, Jin K. Kim, Ricardo L. Peñna, Robert W. Schrier – 1 September 1995 – To test the hypothesis that diminished sodium delivery to the distal tubular site of atrial natriuretic peptide (ANP) action accounts for renal ANP resistance in cirrhosis, 12 cirrhotic patients with ascites were studied at baseline and during the infusion of ANP alone (0.15 μg/kg/min), mannitol alone (4 g/hr), and ANP plus mannitol for 3 hours each.

Ioannis Diamantis, Eva Karamitopoulou, Elias Perentes, Arthur Zimmermann – 1 September 1995 – Forty‐five extrahepatic bile duct carcinomas (i.e., tumors of the region proximal to the duct junction, including Klatskin tumors, tumors of the lower mid‐region, and tumors of the ampulla of Vater) and 11 gallbladder carcinomas were immunohistochemically examined for p53 protein expression, using the DO‐7 monoclonal (mAb) and the CM‐1 polyvalent (pAb) antibodies and an antigen retrieval method.

Stephen Wong, Tony Gauthier, Kelly D. E. Kaita, Gerald Y. Minuk – 1 September 1995 – The purpose of this study was to determine whether all commercially available forms of interferon alfa (IFN α) have the same inhibitory effect on hepatic regeneration and whether this inhibitory effect can be prevented by putrescine, a hepatic growth promotor. Adult male Sprague‐Dawley rats (n = 92) received either IFN α‐2a, 2b, n1, or saline, 0 and 8 hours after partial hepatectomy (PHx) or 16 hours before PHx.